GlassScriptPhysician profile
Edmund A Nahm
NPI 1811230170
$2,438.44
in general payments reported to CMS, 2019-2025
16 companies · $382 in 2025
The $382 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348 · 2020: $344 · 2021: $82.08 · 2022: $117 · 2023: $350 · 2024: $815 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,546.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $580.63 | 2023-2025 | Ayvakit |
| Kaleo, INC. | $421.61 | 2019-2024 | Auvi-Q |
| Optinose US, INC. | $287.16 | 2020-2025 | |
| Genzyme Corporation | $202.44 | 2019-2025 | |
| Alk-Abello, INC | $197.98 | 2019-2024 | Grastek, Ragwitek, Odactra |
| Regeneron Healthcare Solutions, INC. | $169.84 | 2019-2020 | |
| Glaxosmithkline, LLC. | $130.55 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $116.13 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $106.38 | 2023-2025 | Cuvitru |
| Phathom Pharmaceuticals, INC. | $53.32 | 2024-2025 | Voquezna |
| Acclarent, INC | $38.40 | 2019 | |
| Intersect Ent, INC. | $38.10 | 2019 | |
| Hikma Pharmaceuticals USA | $34.04 | 2024 | Ryaltris |
| Pharming Healthcare, INC. | $27.15 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $17.83 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $16.88 | 2025 | Anzupgo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edmund Nahm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.